Hyderabad, Telangana, India, July 2025 – Ganesh Balakrishnan has taken on the role of Chief Commercial Officer at Sekhmet Pharmaventures, bringing with him over two decades of leadership in business development, commercial strategy, and pharmaceutical operations. In this pivotal role, Ganesh will spearhead commercial growth across Sekhmet’s expanding pharmaceutical ventures, including its investments in API and formulation manufacturing facilities.
Ganesh most recently served as Vice President & Head – Business Development (Fermentation & Chemical APIs) at Biological E. Limited, where he led strategic initiatives in business expansion, fermentation technology, and API partnerships. His efforts were instrumental in building new growth avenues and strengthening the company’s position in the global pharmaceutical space.
Prior to that, he had a 7+ year tenure at Piramal Pharma Solutions, where he held progressive roles including Vice President, Head – Established Products, and Head – Corporate Strategy & Development. At Piramal, he played a key role in driving commercial operations, optimizing product portfolios, and crafting strategic partnerships.
Ganesh spent over 14 years at Orchid Pharma, where he served as Senior General Manager and Head of Corporate Strategy & Development, contributing significantly to the company’s international business growth and strategic transformation.
He holds a Bachelor of Pharmacy (Hons.) from BITS Pilani, an MBA in Finance and Marketing from ITM Business School (where he was recognized as the Best Student in Finance), and a Postgraduate Diploma in International Business from Pondicherry University.
About Sekhmet Pharmaventures
Sekhmet Pharmaventures Pvt. Ltd., the Indian arm of Gamot API Pte. Ltd. (Singapore), is a high-growth pharmaceutical investment platform backed by PAG, CX Partners, and Samara Capital. With a vision to make India a key global hub for API and formulation manufacturing, Sekhmet is investing in scalable, quality-driven pharma ventures. Its portfolio includes major acquisitions such as Anjan Drug Pvt. Ltd. and the Optimus Drugs Group of Companies, with continued expansion underway to build a resilient, integrated pharma supply chain.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
